Bioventus acquires BioStructures synthetic bone grafting portfolio
Bioventus, a global leader in orthobiologic solutions, today announced it has acquired BioStructures LLC, a proprietary developer and marketer of bioresorbable bone graft products for a broad range of spinal and orthopaedic surgical applications. The agreement includes the entire portfolio of products as well as its research and development pipeline. In addition, employees of BioStructures will be given offers to join Bioventus. Terms of the acquisition were not disclosed.
“This acquisition will continue to allow the culture of innovation, as well as advance the positive momentum we have built at BioStructures. We are happy to announce the transaction and look forward to the future with confidence and excitement.”
The BioStructures product portfolio includes synthetic, allograft, collagen, and demineralized bone matrix (DBM) solutions for surgeons. Its signature products are:Interface™ Bioactive Bonegraft, a synthetic graft used to repair osseous defects, andSignafuse™ Bioactive Bonegraft Putty comprised of a bi-phasic mineral composite combined with the company’s patented bioactive glass and resorbable polymer carrier.
“The acquisition of BioStructures aligns with our strategy to be a leader in orthobiologics, building on the launch of the Bioventus Surgical business with the OsteoAMP® acquisition in 2014, and our longer term development of the next generation BMP,” said Tony Bihl, CEO of Bioventus. “This now gives Bioventus a broad offering of bone grafting solutions backed by clinical and technical data to benefit patients, surgeons, and hospitals.”
“This is a great event for BioStructures, Bioventus, our customers and our employees. We believe the combination of our product offerings will result in a truly unique and robust portfolio benefiting patients, surgeons and hospitals not found in the market today,” said Russell Cook, BioStructures Chief Executive Officer. “This acquisition will continue to allow the culture of innovation, as well as advance the positive momentum we have built at BioStructures. We are happy to announce the transaction and look forward to the future with confidence and excitement.”
Bioventus will continue to work with the current network of distributors carrying the BioStructures product portfolio and expand that sales footprint to bring these solutions to more surgeons and hospitals throughout the US.
About BioStructures LLC
BioStructures is a leading medical device company focused on developing innovative proprietary platforms in bioresorbable bone graft products for a broad range of spinal and orthopedic fusion procedures. BioStructures’ global mission is to develop and commercialize new and innovative products focused on improving bone regeneration and remodeling for related clinical procedures. For additional information on BioStructures, please visit its website at www.biostructures.net.
Bioventus LLC is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. Bioventus has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical that make it a global leader in active orthopaedic healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.
Bioventus, the Bioventus logo and OsteoAMP are registered trademarks of Bioventus. Interface and Signafuse are trademarks of BioStructures.
Thomas Hill, 919-474-6715